Suppr超能文献

水飞蓟宾,一种可能存在于华蟾素注射液中的治疗肝癌的有效成分。

Bufothionine, a possible effective component in cinobufocini injection for hepatocellular carcinoma.

机构信息

Department of Pharmacy, Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, PR China.

出版信息

J Ethnopharmacol. 2012 Jun 1;141(2):692-700. doi: 10.1016/j.jep.2011.12.018. Epub 2011 Dec 22.

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE

Cinobufacini has been traditionally used in China for the treatment of tumor since hundreds years ago. For recent years, its modern preparation,cinobifucini injection has also obtained satisfactory therapeutic functions for cancer.

MATERIALS AND METHODS

High performance liquid chromatography (HPLC) analysis was applied to determine the content of cinobufagin, resibufogenin and bufothionine in cinobufacin extract liquid and injection; MTT assay and flow cytometric analysis were also respectively used to study the effect of cinobufacini extract liquid, injection and three chemical structures on cells and cell cycles.

RESULTS

HPLC results demonstrated that in cinobufacini extract liquid three ingredients (cinobufagin, resibufogenin and bufothionine) were all monitored while in cinofacini injection only bufothinone was detected; MTT assays showed bufothionine could obviously inhibit the proliferation of human hepatocellular carcinoma cell lines such as SMMC-7721 and BEL-7402 in a dose- and time-dependent manner as well as cinobufagin and resibufogenin; further flow cytometric analysis indicated obvious increases in G2/M phase and decrease in G0/G1 phase when SMMC-7721 cell line exposure to bufothionine (480 μg/ml).

CONCLUSIONS

These results suggested bufothionine could be involved in treatment of human cancer for cinobufacini injection and the mechanism might be relative to induce G2/M phase cell cycle arrest.

摘要

民族药理学相关性

数百年来,蟾酥一直被中国传统用于治疗肿瘤。近年来,其现代制剂蟾毒灵注射液也在癌症治疗中取得了满意的疗效。

材料与方法

采用高效液相色谱法(HPLC)测定蟾酥提取物液和注射液中蟾毒灵、脂蟾毒配基和蟾毒它灵的含量;分别采用 MTT 法和流式细胞术分析蟾酥提取物液、注射液和三种化学结构对细胞和细胞周期的影响。

结果

HPLC 结果表明,蟾酥提取物液中三种成分(蟾毒灵、脂蟾毒配基和蟾毒它灵)均有监测,而蟾毒灵注射液中仅检测到蟾毒它灵;MTT 试验表明,蟾毒它灵能明显抑制人肝癌细胞株 SMMC-7721 和 BEL-7402 的增殖,呈剂量和时间依赖性,而蟾毒灵和脂蟾毒配基也有一定的抑制作用;进一步的流式细胞术分析表明,SMMC-7721 细胞株暴露于蟾毒它灵(480μg/ml)时,G2/M 期明显增加,G0/G1 期明显减少。

结论

这些结果表明,蟾毒它灵可能参与了蟾毒灵注射液治疗人类癌症的作用,其机制可能与诱导 G2/M 期细胞周期阻滞有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验